Atlas Trials

Johnson & Johnson Private Limited

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Johnson & Johnson Private Limited

RecordFirmDate
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) (NCT07141004)Johnson & Johnson Private Limited2025-08-12
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma (NCT07030517)Johnson & Johnson Private Limited2025-05-22
A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes (NCT04288778)Johnson & Johnson Private Limited2020-11-25
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion (NCT03190330)Johnson & Johnson Private Limited2019-06-26
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent (NCT03768960)Johnson & Johnson Private Limited2019-06-10
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis (NCT03733925)Johnson & Johnson Private Limited2019-01-07
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting (NCT03604224)Johnson & Johnson Private Limited2018-09-05
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India (NCT03476655)Johnson & Johnson Private Limited2018-04-28
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer (NCT02608359)Johnson & Johnson Private Limited2016-05-31

Track Johnson & Johnson Private Limited automatically

Every clearance here is in the API, with alerts when new ones post.